Human Trials

Acceleron completes target enrollment in phase 2 trial of Sotatercept in PAH

Acceleron Pharma, a biopharmaceutical company focused on the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, has completed target enrollment of patients with pulmonary arterial hypertension (PAH) in the PULSAR Phase 2 trial of sotatercept.

Imbrium initiates phase 2 study of IMB-115 in insomnia associated with alcohol cessation

Imbrium Therapeutics, an operating subsidiary of Purdue Pharma, is advancing its novel, potentially first-in-class small molecule IMB-115 (previously referred to as IT-1315) to a Phase 2 clinical study following favorable results from Phase 1 studies evaluating the molecule’s safety and tolerability, including its potential for abuse and interaction with alcohol.

TILT Biotherapeutics to evaluate TILT-123, avelumab combo in solid tumours

TILT Biotherapeutics has joined forces with Merck and Pfizer to evaluate the combination of its oncolytic adenovirus TILT-123 ((Ad5/3-E2F-D24-TNFa-IRES-IL2) with the duo’s avelumab for the treatment of solid tumours that are refractory to routine modalities.

NantKwest launches phase 1 trial with targeted PD-L1 t-haNK cell therapy in patients with solid tumors

NantKwest announced that the company’s PD-L1 t-haNK investigational new drug application (IND) has cleared FDA review and the program has now transitioned to a first-in-human clinical trial in patients with locally advanced or metastatic solid cancers.

Horizon Therapeutics initiates MIRROR trial evaluating KRYSTEXXA in combination with methotrexate

Horizon Therapeutics has announced the initiation of a clinical trial evaluating KRYSTEXXA (pegloticase injection) in combination with methotrexate as a strategy to increase the durability of response for patients living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.

RIBOMIC announces positive top-line results from phase 1/2a trial of rbm-007 in wet AMD

RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced positive top-line results from its SUSHI study, Phase 1/2a single ascending dose clinical study of RBM-007, anti-FGF2 aptamer, in nine subjects with wet Age-Related Macular Degeneration (wet AMD).

Ironwood and Allergan’s linaclotide succeeds in phase 3b trial in IBS-C

Ironwood Pharmaceuticals and Allergan said that their guanylate cyclase-C (GC-C) agonist LINZESS (linaclotide) 290mcg succeeded in a phase 3b trial on multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation (IBS-C).

Rocket begins patient dosing in phase 1 trial of RP-A501 in Danon disease

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that patient dosing has commenced in the open-label, Phase 1 clinical trial of RP-A501, the Company’s adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease.

Boehringer, OSE doses first patient in phase 1 trial of SIRPα antagonist monoclonal antibody

Boehringer Ingelheim and OSE Immunotherapeutics announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063, formerly OSE-172, a first-in-class monoclonal antibody antagonist of SIRPα, being studied in patients with advanced solid tumours.